Reshaping Tumor Microenvironments via Immunotherapies

10:15 AM - 10:55 AM (JST), Tuesday, March 5, 2019 ・ 2nd Floor
Current CAR-T therapies have shown significant benefits attacking hematological malignancies, and currently approved checkpoint inhibitors are highly but selectively effective in their impact on solid tumors. This session will examine the next wave of innovation in immunotherapies for leveraging knowledge of how tumor microenvironments develop to create treatments able to demonstrate more durable effects on shrinking tumors across wider ranges of patients.